ArticleInvestigative ophthalmology & visual science2026
Establishment of Mouse Meibomian Gland Organoids for In Vitro Modeling of Meibomian Gland Dysfunction.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To establish a three-dimensional model of the mouse meibomian gland (MG) and to recapitulate meibomian gland dysfunction (MGD) for pathological investigations in MGD. Methods: Primary mouse MG epithelial cells (MGECs) were embedded in Matrigel and expanded in serum-free medium, followed by the addition of extra growth factors to induce branching. Organoids were characterized by light microscopy, immunofluorescence, lipid staining, transmission electron microscopy, and RNA sequencing. The MGD organoid model was induced by interleukin-1β (IL-1β). Characteristics after orthotopic transplantation were assessed through hematoxylin and eosin and immunofluorescence staining. Results: Mouse MGECs undergo spheroid formation, budding, and branching, forming organoids characterized by lipid- and debris-filled central lumens, surrounded by KRT6+ ductal cells, with Ki67+ progenitor cells present at early stages. The progenitor marker LRIG1, and the basal epithelial cell marker KRT5 were expressed throughout the organoids. Differentiation markers peroxisome proliferator-activated receptor gamma (PPARγ) and acyl-CoA wax alcohol acyltransferase 2 (AWAT2) were detectable at days 7, 14, and 35. Transcriptomic analysis revealed upregulation of signaling pathways related to development in organoids. IL-1β exposure arrested organoid development, inhibited lipid accumulation, and induced hyperkeratinization of MG organoids, which was reversed by SB203580, an inhibitor of the p38 mitogen-activated protein kinase (MAPK) signaling pathway, or rosiglitazone, an agonist of the PPARγ signaling pathway. Transplanted organoids survived by 7 days with retained lipid droplets and ductal markers. Conclusions: We developed mouse MG organoids that exhibited ductal-acinar architecture, sustained lipid production, and maintained stem/progenitor cell expression. Organoids modeled key features of MGD through exposure to IL-1β and can respond to targeted therapy. The system offered a promising platform for MGD research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.